NCT01325285

The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 14 (estimated)
• Sponsor: University of Toronto · Academic / Other
• Sex: All
• Age: 18 Years – 30 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine how intraocular pressure responds to changes in the levels of carbon dioxide or oxygen that a healthy individual inspires.

Detailed description

In response to changes in the composition of inhaled gases, blood vessels will dilate or constrict. As a result, hypercapnia or hyperoxia may affect the production and drainage of aqueous humour in the anterior chamber of the eye. The balance between the production and drainage of the aqueous humour determines the intraocular pressure. As this system is hydrodynamic, it is expected that any increase or decrease in the production of aqueous humour due to dilation or constriction of the capillaries within the ciliary body will be compensated by increased or decreased drainage at the trabecular meshwork. Therefore intraocular pressure is not expected to show a response to hypercapnia or hyperoxia, but this supposition needs to be tested in a stably controlled manner of inducing inhaled gas provocations. This study will measure the intraocular pressure at varying levels of hypercapnia and hyperoxia using a sequential rebreathing circuit and automated gas blender. This will allow the precise targeting and stable control of end-tidal partial pressure values of carbon dioxide and oxygen. In this study, intraocular pressure will be measured at seven different inhaled gas stages. The seven stages are as follows: 1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg) 2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg) 3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg) 4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg) 5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg) 6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg) 7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)

Conditions

• Intraocular Pressure

Interventions

Type	Name	Description
DEVICE	RespirAct	Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each: 1. Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg) 2. 10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg) 3. 20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg) 4. Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg) 5. 250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg) 6. 500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg) 7. Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)

Timeline

• Start date: 2011-08-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2011-03-29
• Last updated: 2011-08-18

Locations

1 site across 1 country: Canada